Literature DB >> 34056682

Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients.

Koichi Yamaguchi1, Aya Yamaguchi2, Miki Itai3, Yuji Onuki2, Yuki Shin2, Shogo Uno2, Chiharu Hanazato2, Kohei Taguchi3, Kazue Umetsu3, Masaki Aikawa2, Shunichi Kouno2, Masao Takemura3, Kenichiro Hara2, Shinsuke Motegi4, Mayuko Tsukida4, Fumie Ota4, Yoshito Tsukada4, Mitsuru Motegi3, Masao Nakasatomi5, Toru Sakairi5, Hidekazu Ikeuchi5, Yoriaki Kaneko5, Keiju Hiromura5, Toshitaka Maeno2.   

Abstract

Anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) occurs in elderly people, and patients with anti-myeloperoxidase autoantibodies (MPO-ANCA)-positive AAV are often complicated with interstitial lung disease (ILD). This study aimed to evaluate the age-related clinical features of elderly patients with MPO-ANCA-positive AAV-ILD. This study retrospectively investigated 63 patients with MPO-ANCA-positive AAV-ILD, all of whom were 65 years or older at diagnosis. Clinical characteristics, causes of death and survival rates among three groups stratified by age (65-74 years, n = 29; 75-79 years, n = 18; over 80 years, n = 16) were compared. This study also examined the association with severe infections in these patients. Among the three age groups, there were significant differences in sex (P = 0.032), serum Krebs von den Lungen-6 (P < 0.01), and total ground-glass opacity score (P = 0.011). The causes of death were mainly severe infections and complications of ILD. Kaplan-Meier curve analysis showed a significantly lower 5-year survival rate in the oldest group (P < 0.01). Regarding severe infections in these patients, the 5-year cumulative incidence of severe infections was higher in the patients receiving steroid pulse therapy (P = 0.034). The clinical characteristics of MPO-ANCA-positive AAV-ILD differ with age in elderly patients, with age being an important poor prognostic factor in these patients. The administration of steroid pulse therapy is a significant risk factor of severe infection in MPO-ANCA-positive elderly patients with AAV-ILD.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Age; Anti-neutrophil cytoplasmic antibody; Elderly; Interstitial lung disease

Mesh:

Substances:

Year:  2021        PMID: 34056682     DOI: 10.1007/s00296-021-04891-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  34 in total

Review 1.  Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.

Authors:  Lei Shi
Journal:  Rheumatol Int       Date:  2017-09-27       Impact factor: 2.631

2.  Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.

Authors:  Sara Monti; Anthea Craven; Catherine Klersy; Carlomaurizio Montecucco; Roberto Caporali; Richard Watts; Peter A Merkel; Raashid Luqmani
Journal:  Rheumatology (Oxford)       Date:  2021-02-01       Impact factor: 7.580

3.  Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Authors:  Maria Weiner; Su Mein Goh; Aladdin J Mohammad; Zdenka Hruskova; Anisha Tanna; Annette Bruchfeld; Daina Selga; Zdenka Chocova; Kerstin Westman; Per Eriksson; Charles D Pusey; Vladimir Tesar; Alan D Salama; Mårten Segelmark
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-22       Impact factor: 8.237

4.  ANCA-associated glomerulonephritis in the very elderly.

Authors:  Andrew S Bomback; Gerald B Appel; Jai Radhakrishnan; Shayan Shirazian; Leal C Herlitz; Barry Stokes; Vivette D D'Agati; Glen S Markowitz
Journal:  Kidney Int       Date:  2010-12-15       Impact factor: 10.612

5.  Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.

Authors:  R A Watts; S E Lane; G Bentham; D G Scott
Journal:  Arthritis Rheum       Date:  2000-02

6.  ANCA vasculitis in the elderly.

Authors:  Deana D Hoganson; Aaron M From; Clement J Michet
Journal:  J Clin Rheumatol       Date:  2008-04       Impact factor: 3.517

7.  Clinical features and outcomes in patients with elderly-onset anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Shuzo Sato; Makiko Yashiro; Naoki Matsuoka; Tomoyuki Asano; Hiroko Kobayashi; Hiroshi Watanabe; Kiyoshi Migita
Journal:  Geriatr Gerontol Int       Date:  2018-08-30       Impact factor: 2.730

Review 8.  Pathogenesis and therapeutic interventions for ANCA-associated vasculitis.

Authors:  Daigo Nakazawa; Sakiko Masuda; Utano Tomaru; Akihiro Ishizu
Journal:  Nat Rev Rheumatol       Date:  2019-02       Impact factor: 20.543

9.  Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).

Authors:  Vinod Chandran; Désirée van der Heijde; Roy M Fleischmann; Eric Lespessailles; Philip S Helliwell; Hideto Kameda; Ruben Burgos-Vargas; Janelle S Erickson; Suchitrita S Rathmann; Aubrey Trevelin Sprabery; Julie A Birt; Catherine L Shuler; Gaia Gallo
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

10.  Long-term outcomes in elderly patients with ANCA-associated vasculitis.

Authors:  Dominic McGovern; Sam P Williams; Katrina Parsons; Tariq E Farrah; Peter J Gallacher; Eve Miller-Hodges; David C Kluth; Robert W Hunter; Neeraj Dhaun
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

View more
  1 in total

Review 1.  Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

Authors:  Hideaki Yamakawa; Yuko Toyoda; Tomohisa Baba; Tomoo Kishaba; Taiki Fukuda; Tamiko Takemura; Kazuyoshi Kuwano
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.